K262683 · bioMérieux, Inc. · LON · Nov 3, 2026 · Microbiology
Device Facts
Record ID
K262683
Device Name
VITEK PRO
Applicant
bioMérieux, Inc.
Product Code
LON · Microbiology
Decision Date
Nov 3, 2026
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 866.1645
Device Class
Class 2
Attributes
AI/ML
Indications for Use
The VITEK PRO is intended for the automated quantitative and/or qualitative antimicrobial susceptibility testing of isolated colonies for most clinically significant aerobic Gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., and yeast. The VITEK PRO is also intended for the automated identification of most clinically significant anaerobic organisms and Corynebacterium species, fermenting and nonfermenting Gram-negative bacilli, Gram-positive organisms, fastidious organisms, and yeasts and yeast-like organisms.
Device Story
VITEK PRO is an automated diagnostic system for microbial identification (ID) and antimicrobial susceptibility testing (AST). It processes isolated colonies inoculated into saline, adjusted to 0.5 McFarland standard (manually or via VITEK FLEXPREP variable pipetting). The instrument performs autoinoculation into 64-well test cards, incubation, and optical readings (660 nm) every 15 minutes. VITEK 2 Systems Software analyzes growth-based turbidity changes using discriminate and growth pattern analysis. The Advanced Expert System (AES) provides result validation and phenotype interpretation. Results are quantitative (MIC) or qualitative, transferable to LIS via bidirectional interface. Used in clinical microbiology labs by trained professionals. Benefits include automated workflow, standardized inoculum preparation, and systematic interpretation of resistant phenotypes.
Clinical Evidence
Bench testing only. Reproducibility study across three sites and three instruments (GN, GP, ST, YS cards) showed ≥95% reproducibility. Accuracy study compared VITEK PRO to VITEK 2 manual mode across three dilution methods (Variable Pipetting, Auto Load & Go, Manual Load & Go). Essential Agreement (EA) was >95% for all card types (GN, GP, ST, YS). Purity plates confirmed 100% monomicrobial growth.
Technological Characteristics
Automated diagnostic system; 64-well test cards; 660 nm optical reading; vacuum filling/heat sealing; incubation at 35.5°C ± 1°C. Supports 60-120 card capacity. Connectivity via bidirectional computer interface (LIS). Software-based analysis using growth-based turbidity and discriminate analysis. Complies with IEC 61010-1, IEC 61326-2-6, and IEC 62471.
Indications for Use
Indicated for automated ID and AST of isolated colonies of aerobic Gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., yeast, anaerobic organisms, Corynebacterium species, fermenting/nonfermenting Gram-negative bacilli, Gram-positive organisms, and fastidious organisms. For prescription use only.
Regulatory Classification
Identification
A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.
Special Controls
*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
Predicate Devices
VITEK 2 System (N50510/S82)
Submission Summary (Full Text)
{1}
[LOGO]
FDA
U.S. FOOD & DRUG
ADMINISTRATION
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
## DECISION SUMMARY
INSTRUMENT ONLY
### I Background Information:
A 510(k) Number
K262683
B Applicant
bioMérieux, Inc.
C Proprietary and Established Names
VITEK PRO
D Regulatory Information
| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| LON | Class II | 21 CFR 866.1645 - Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System | MI - Microbiology |
### II Submission/Device Overview:
A Purpose for Submission:
To obtain a substantial equivalence determination for the VITEK PRO.
B Type of Test:
In vitro diagnostic test software used for identification and antimicrobial susceptibility testing of microorganisms.
### III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov
{2}
# **B Indication(s) for Use:**
The VITEK PRO is intended for the automated quantitative and/or qualitative antimicrobial susceptibility testing of isolated colonies for most clinically significant aerobic Gram-negative bacilli, *Staphylococcus* spp., *Enterococcus* spp., *Streptococcus* spp., and yeast.
The VITEK PRO is also intended for the automated identification of most clinically significant anaerobic organisms and *Corynebacterium* species, fermenting and nonfermenting Gram-negative bacilli, Gram-positive organisms, fastidious organisms, and yeasts and yeast-like organisms.
# **C Special Conditions for Use Statement(s):**
Rx - For Prescription Use Only
The following VITEK 2 AST Cards may be used with the VITEK PRO:
GN, GP, ST, YS AST cards
# **IV Device/System Characteristics:**
# **A Device Description:**
The VITEK PRO is intended for laboratory use by professional users who are trained in microbiology and good laboratory practices. The VITEK PRO instrument is an automated diagnostic system for identification (ID) and antimicrobial susceptibility testing (AST). A single instrument supports test cards in capacities of 60 and 120. A system is designed to support test card capacities of 60 to 480 (in increments of 60) and provide automated reagent sample preparation, processing, incubation, optical readings, and collection for disposal.
The VITEK 2 Systems Software receives the instrument optical readings and performs data analysis. The data analysis consists of different parameters that are calculated to characterize the activity of the card using discriminate analysis and growth pattern analysis. The instrument then ejects the completed reagent card into the waste collection station for disposal. A bidirectional computer interface may transfer results automatically to the user's laboratory information system (LIS). A quality control system is available to track the quality control results of the test cards. The Advanced Expert System (AES, Clinical Use) is available to provide online, systematic validation of results, and interpretation of resistant phenotypes found during susceptibility testing.
The VITEK PRO is intended for organism identification and AST results (quantitative MIC values). The VITEK 2 Systems Software (e.g., LIS and AES) uses the organism ID and antimicrobial agent MIC values to determine the qualitative categorical interpretation based on the best phenotype match.
# **B Instrument Description Information:**
1. Instrument Name:
VITEK PRO
K262683 - Page 2 of 12
{3}
# 2. Specimen Identification:
Specimen identification is logged in the VITEK PRO patient information workspace using a manual entry to identify specimen/patient information, and 2D barcode to associate an isolate to a specific VITEK 2 identification or susceptibility testing card. This may be completed at the instrument, referred to as load and go, using the provided external monitor and keyboard, or may be completed utilizing the VITEK FLEXPREP virtual cassette option.
# 3. Specimen Sampling and Handling:
Isolated colonies are inoculated into saline and then the density is manually adjusted to a 0.5 McFarland standard using a VITEK 2 DENSICHECK. Alternatively, the user can utilize an automatic dilution using the VITEK FLEXPREP Variable Pipetting application for the expanded McFarland range as shown in Table 1 for the GN, GP, ST and YS cards to adjust the density.
After the configuration option is selected from 'VITEK FLEXPREP' or 'Load & Go', specimens and a cassette are loaded into the instrument for the autoinoculation into test cards. Then, the cassette is transferred automatically into the load/unload station for incubation after density adjustment.
Table 1. McFarland Ranges for AST Dilution Preparation
| Dilution Mode | Mode | McFarland Ranges |
| --- | --- | --- |
| Automatic Dilution | Variable Pipetting | Expanded Range (0.40 – 1.00) McFarland for GN, GP, ST and (1.50 – 3.00) for YS |
| | Auto Load & Go (Variable Pipetting OFF) | Standard Range (0.50 – 0.63) McFarland for GN, GP, ST and (1.80 – 2.20) for YS |
| Manual Dilution | Manual Load & Go | Standard Range (0.50 – 0.63) McFarland for GN, GP, ST and (1.80 – 2.20) for YS |
# 4. Calibration:
There is no direct calibration procedures associated with the VITEK PRO. The scheduled user maintenance includes instrument diagnostics to check system information, test the vacuum function, and check the instrument temperature. Additional user maintenance may include cleaning the optics, carousel maintenance, and general cleaning practices.
# 5. Quality Control:
Quality Control (QC) testing of the VITEK PRO should be performed as dictated by the protocol in the package insert of each AST card and antimicrobial agent. The purpose of QC testing is to monitor performance of the VITEK PRO as well as the proficiency of the laboratory personnel who use the system. The QC testing is performed with the manufacturer recommended QC strains. The QC workflow follows the same steps as the sample workflow. The QC results are generated and displayed on the user interface indicating the expected QC MIC range, the VITEK PRO AST interpretive criteria call, and whether the relevant antimicrobial agents for the organism have passed or failed.
K262683 - Page 3 of 12
{4}
During validation testing of each AST card, indicated antimicrobial agents and CLSI recommended reference strains are summarized in Table 2. Purity of all the isolates was confirmed by purity plates, with 100% of purity plates showing monomicrobial growth. Results are summarized in Table 3, and the quality control testing is acceptable.
Table 2. Quality Control Antimicrobial Agents and Strains Tested
| AST Card | Antimicrobial Agent | Strain |
| --- | --- | --- |
| GN AST card | Amoxicillin/clavulanic acid, Aztreonam, Cefazolin, Cefepime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Ertapenem, ESBL (extended spectrum beta-lactamase) Screen Test, Meropenem/vaborbactam, Minocycline, Tigecycline, Tobramycin, Trimethoprim/sulfamethoxazole | Escherichia coli, ATCC 25922 Escherichia coli, ATCC 35218 Klebsiella quasipneumoniae (previously K. pneumoniae), ATCC 700603 Klebsiella pneumoniae, ATCC BAA-2814 Pseudomonas aeruginosa ATCC 27853 |
| GP AST cards | Ampicillin, Cefoxitin Screen Test, Clindamycin, Daptomycin, Erythromycin, Gentamicin High Level Screen Test, Linezolid, Moxifloxacin, Nitrofurantoin, Oxacillin, Streptomycin High Level Screen Test, Tetracycline, Vancomycin | Enterococcus faecalis, ATCC 29212 Enterococcus faecalis, ATCC 51299 Staphylococcus aureus, ATCC 29213 Staphylococcus aureus, ATCC BAA-1026 |
| ST AST card | Benzylpenicillin, Ceftriaxone, Clindamycin, Erythromycin, ICR (Inducible Clindamycin Resistance) Screen Test, Levofloxacin, Linezolid, Tetracycline, Trimethoprim/sulfamethoxazole, Vancomycin | Staphylococcus aureus, ATCC 29213 Staphylococcus aureus, ATCC BAA-977 Streptococcus pneumoniae, ATCC 49619 |
| YS AST card | Caspofungin, Fluconazole, Micafungin | Candida krusei, ATCC 6258 Candida parapsilosis, ATCC 22019 |
All gram-negative (GN), gram-positive (GP) and Streptococcus (ST) reproducibility isolates were sub-cultured twice onto trypticase soy agar and incubated appropriately at 35 ± 2 °C, for 18 – 24 hours (GN and GP) or 18 – 20 hours (ST) before testing. All yeast (YS) isolates were sub-cultured twice onto Sabouraud dextrose agar and incubated at 35 ± 2 °C for 24 hours. MIC values for each drug/organism combination were compared to the expected MIC range. Purity of all the suspensions was confirmed by purity plates. A minimum of 20 replicates of each QC strain were tested at one clinical trial site on the VITEK PRO and the VITEK 2 60 instruments. For the VITEK PRO, the automatic dilution mode with Variable Pipetting ON (Variable Pipetting) was assessed across an expanded McFarland range. In addition, the automatic dilution mode (Auto Load & Go) and the manual dilution mode (Manual Load & Go) were assessed with a standard McFarland range.
Results are summarized in Table 3 stratified by each AST card. The cumulative reporting and stratification by each card are presented for simplicity and are based on the analysis for
K262683 - Page 4 of 12
{5}
each drug/organism combination which revealed acceptable quality control test results.
Results from expanded range evaluation showed similar results across different initial ranges irrespective of the initial McFarland (low, standard, or high range).
Table 3. Quality Control Results Stratified by AST Card
| AST Card | Number (%) of MIC values within established QC Range | | | |
| --- | --- | --- | --- | --- |
| | VITEK PRO Variable Pipetting | VITEK PRO Auto Load & Go | VITEK PRO Manual Load & Go | VITEK 2 Manual |
| GN | 672/675 (99.6%) | 670/675 (99.3%) | 663/665 (99.7%) | 672/675 (99.6%) |
| GP | 600/600 (100%) | 600/600 (100%) | 600/600 (100%) | 598/600 (99.7%) |
| ST | 262/264 (99.2%) | 249/253 (98.4%) | 259/264 (98.1%) | 261/264 (98.9%) |
| YS | 150/150 (100%) | 123/123 (100%) | 120/120 (100%) | 120/120 (100%) |
### V Substantial Equivalence Information:
#### A Predicate Device Name(s):
VITEK 2 System
#### B Predicate 510(k) Number(s):
N50510/S82
#### C Comparison with Predicate(s):
| Device & Predicate Device(s): | K262683VITEK PRO | N50510/S82VITEK 2 System |
| --- | --- | --- |
| Device Trade Name | VITEK PRO | VITEK 2 System |
| General Device Characteristic Similarities | | |
| Intended Use/Indications for Use | The VITEK PRO is intended for the automated quantitative and/or qualitative antimicrobial susceptibility testing of isolated colonies for most clinically significant aerobic Gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., and yeast.The VITEK PRO is also intended for the automated identification of most clinically | The VITEK 2 is intended to be used for the automated quantitative or qualitative susceptibility testing of isolated colonies for most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae and S. pneumoniae. |
K262683 - Page 5 of 12
{6}
| Device & Predicate Device(s): | K262683 VITEK PRO | N50510/S82 VITEK 2 System |
| --- | --- | --- |
| | significant anaerobic organisms and Corynebacterium species, fermenting and nonfermenting Gram-negative bacilli, Gram-positive organisms, fastidious organisms, and yeasts and yeast-like organisms. | |
| Test Cards | VITEK 2 AST 64-well cards | Same |
| Cards per Cassette | 15 cards/cassette | Same |
| AST Card Inoculum | Isolated colonies prepared with a DENSICHECK densitometer and autoinoculation after loading specimens and AST card into the instrument | Same |
| Filling and Sealer process | Vacuum filled and automated heat seal | Same |
| Incubation and Reading | Automated, 35.5°C +/- 1° with automated readings every 15 minutes with 660 nm optics | Same |
| AST analysis | Analysis of changes in growth-based turbidity | Same |
| Advanced Expert System | Yes | Same |
| Waste | Automated removal of ejected test cards to waste container at end of cycle | Same |
| LIS communication | Bidirectional Computer Interface (BCI) | Same |
| Results Reported | Identification (ID), quantitative (MIC) and/or qualitative AST results | Same |
K262683 - Page 6 of 12
{7}
| Device & Predicate Device(s): | K262683 VITEK PRO | N50510/S82 VITEK 2 System |
| --- | --- | --- |
| **General Device Characteristic Differences** | | |
| Test Setup | VITEK FLEXPREP | Smart Carrier Station or VITEK FLEXPREP |
| Card Capacity | 60 cards with licenses to expand to 120 cards in one instrument | 60 for VITEK 2 and 120 for VITEK 2 XL |
| AST Dilution Preparation | Manual with Standard McFarland Range Automatic with Standard McFarland Range Automatic with Variable Pipetting with expanded McFarland Range | Manual or Automatic with Standard McFarland Range |
### VI Standards/Guidance Documents Referenced:
- Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA
- Guidance for Content of Premarket Submissions for Device Software Functions
- Guidance for Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
- Guidance for Electromagnetic Compatibility (EMC) of Medical Devices
The following FDA-recognized Consensus Standards were referenced and pertain to device and study design for the VITEK PRO:
- IEC 61326-2-6 Electrical equipment for measurement control and laboratory use - EMC requirements - Part 2-6: Particular requirements - In vitro diagnostic (IVD) medical equipment (Edition 3.0 2020-10)
- IEC 61010-1 Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General requirements (Edition 3.1 2017-01 CONSOLIDATED VERSION)
- IEC 62471 Photobiological safety of lamps and lamp systems (First edition 2006-07)
### VII Performance Characteristics (if/when applicable):
#### A Analytical Performance:
##### 1. Precision/Reproducibility:
The reproducibility of MIC results was evaluated with VITEK PRO. For this study, three instruments were used at three testing sites. The following VITEK AST test card panels were
K262683 - Page 7 of 12
{8}
used during testing: Gram-Negative (GN), Gram-Positive (GP), Streptococcus (ST) and Yeast (YS). All GN, GP and ST reproducibility isolates were sub-cultured twice onto trypticase soy agar and incubated appropriately at 35 ± 2 °C, for 18 – 24 hours (GN and GP) or 18 – 20 hours (ST) before testing. All yeast isolates were sub-cultured twice onto Sabouraud dextrose agar and incubated at 35 ± 2 °C for 24 hours. Each reproducibility isolate was tested on the VITEK PRO using the three dilution methods; Automatic Dilution with Variable Pipetting ON (Variable Pipetting), Automatic Dilution with Variable Pipetting OFF (Auto Load & Go), and Manual Dilution with Standard McFarland Range (Manual Load & Go). The reproducibility set was tested in triplicate over three days at three clinical trial sites per instrument producing at least 270 results per antimicrobial per dilution method (10 organisms × 3 replicates × 3 sites × 3 days = 270). For all antimicrobials evaluated, best-case and worst-case reproducibility was ≥95%. Additionally, purity plates were analyzed for monomicrobial growth. All purity plates displayed monomicrobial growth. The list of organism groups and antimicrobial agents tested in the reproducibility study is shown in Table 4. Results are summarized in Table 5-7 stratified by each AST card. The cumulative reporting and stratification by each card are presented for simplicity and are based on the analysis for each drug/organism combination which revealed acceptable reproducibility results.
Table 4. List of Organism groups and Antimicrobial Agents for Reproducibility Testing
| AST card | Organism group | Antimicrobial Agents |
| --- | --- | --- |
| GN AST card | Enterobacterales, Acinetobacter spp., and/or Pseudomonas aeruginosa | Amoxicillin/clavulanic acid, Aztreonam, Cefazolin, Cefepime, Ceftazidime, Ciprofloxacin, Ceftriaxone, Ertapenem, ESBL Screen Test, Meropenem/vaborbactam, Minocycline, Tigecycline, Tobramycin, and Trimethoprim/sulfamethoxazole |
| GP AST card | Enterococcus spp. and/or Staphylococcus spp. | Ampicillin, Cefoxitin Screen Test, Clindamycin, Daptomycin, Erythromycin, Gentamicin High Level Screen Test, Linezolid, Moxifloxacin, Nitrofurantoin, Oxacillin, Streptomycin High Level Screen Test, Tetracycline, and Vancomycin |
| ST AST card | Streptococcus spp. | Benzylpenicillin, Ceftriaxone, Clindamycin, Erythromycin, ICR Screen Test, Levofloxacin, Linezolid, Tetracycline, Trimethoprim/sulfamethoxazole, and Vancomycin |
| YS AST card | Candida spp. | Caspofungin, Fluconazole, and Micafungin |
Table 5. Reproducibility Results Stratified by AST card (Variable Pipetting)
| AST card | Testing Sites | Best case (%) | Worst case (%) |
| --- | --- | --- | --- |
| GN AST card | Site 1 | 1250/1260 (99.2%) | 1224/1260 (97.1%) |
| | Site 2 | 1249/1260 (99.1%) | 1214/1260 (96.3%) |
| | Site 3 | 1241/1260 (98.5%) | 1213/1260 (96.3%) |
| GN AST card total | | 3740/3780 (98.9%) | 3651/3780 (96.6%) |
| GP AST card | Site 1 | 1164/1170 (99.8%) | 1147/1170 (99.3%) |
| | Site 2 | 1161/1170 (99.7%) | 1136/1170 (99.0%) |
| | Site 3 | 1152/1170 (99.5%) | 1128/1170 (98.8%) |
| GP AST card total | | 3477/3510 (99.1%) | 3411/3510 (97.2%) |
K262683 - Page 8 of 12
{9}
| AST card | Testing Sites | Best case (%) | Worst case (%) |
| --- | --- | --- | --- |
| ST AST card | Site 1 | 896/900 (99.6%) | 888/900 (98.7%) |
| | Site 2 | 894/900 (99.3%) | 889/900 (98.8%) |
| | Site 3 | 892/900 (99.1%) | 882/900 (98.0%) |
| ST AST card total | | 2682/2700 (99.3%) | 2659/2700 (98.5%) |
| YS AST card | Site 1 | 265/270 (98.1%) | 265/270 (98.1%) |
| | Site 2 | 270/270 (100%) | 269/270 (99.6%) |
| | Site 3 | 270/270 (100%) | 270/270 (100%) |
| YS AST card total | | 805/810 (99.4%) | 804/810 (99.3%) |
**Table 6. Reproducibility Results Stratified by AST card (Auto Load & Go)**
| AST card | Testing Sites | Best case (%) | Worst case (%) |
| --- | --- | --- | --- |
| GN AST card | Site 1 | 1249/1260 (99.1%) | 1223/1260 (97.1%) |
| | Site 2 | 1243/1260 (98.7%) | 1220/1260 (96.8%) |
| | Site 3 | 1246/1260 (98.9%) | 1231/1260 (97.7%) |
| GN AST card total | | 3738/3780 (98.9%) | 3674/3780 (97.2%) |
| GP AST card | Site 1 | 1156/1170 (99.6%) | 1139/1170 (99.1%) |
| | Site 2 | 1166/1170 (99.9%) | 1138/1170 (99.1%) |
| | Site 3 | 1161/1170 (99.7%) | 1147/1170 (99.3%) |
| GP AST card total | | 3483/3510 (99.2%) | 3424/3510 (97.5%) |
| ST AST card | Site 1 | 889/900 (98.8%) | 884/900 (98.2%) |
| | Site 2 | 891/900 (99.0%) | 880/900 (97.8%) |
| | Site 3 | 897/900 (99.7%) | 888/900 (98.7%) |
| ST AST card total | | 2677/2700 (99.1%) | 2652/2700 (98.2%) |
| YS AST card | Site 1 | 265/270 (98.1%) | 265/270 (98.1%) |
| | Site 2 | 270/270 (100%) | 269/270 (99.6%) |
| | Site 3 | 270/270 (100%) | 270/270 (100%) |
| YS AST card total | | 805/810 (99.4%) | 804/810 (99.3%) |
**Table 7. Reproducibility Results Stratified by AST card (Manual Load & Go)**
| AST card | Testing Sites | Best case (%) | Worst case (%) |
| --- | --- | --- | --- |
| GN AST card | Site 1 | 1244/1260 (98.7%) | 1225/1260 (97.2%) |
| | Site 2 | 1244/1260 (98.7%) | 1235/1260 (98.0%) |
| | Site 3 | 1246/1260 (98.9%) | 1221/1260 (96.9%) |
| GN AST card total | | 3734/3780 (98.8%) | 3681/3780 (97.4%) |
| GP AST card | Site 1 | 1164/1170 (99.8%) | 1147/1170 (99.3%) |
| | Site 2 | 1162/1170 (99.8%) | 1139/1170 (99.1%) |
| | Site 3 | 1152/1170 (99.5%) | 1116/1170 (98.5%) |
| GP AST card total | | 3478/3510 (99.1%) | 3400/3510 (96.9%) |
| ST AST card | Site 1 | 892/900 (99.1%) | 884/900 (98.2%) |
| | Site 2 | 888/900 (98.7%) | 879/900 (97.7%) |
| | Site 3 | 893/900 (99.2%) | 887/900 (98.6%) |
| ST AST card total | | 2673/2700 (99.0%) | 2650/2700 (98.1%) |
| YS AST card | Site 1 | 270/270 (100%) | 269/270 (99.6%) |
| | Site 2 | 270/270 (100%) | 269/270 (99.6%) |
| | Site 3 | 270/270 (100%) | 270/270 (100%) |
| YS AST card total | | 810/810 (100%) | 808/810 (99.8%) |
K262683 - Page 9 of 12
{10}
# 2. Linearity:
Not applicable.
# 3. Analytical Specificity/Interference:
Not applicable.
# 4. Accuracy (Instrument):
The accuracy of MICs obtained by the VITEK PRO was evaluated testing representative strains of clinically relevant microorganisms with the VITEK AST cards. The studies evaluated each of the following dilution methods and modes:
A. The automatic dilution mode with Variable Pipetting ON (Variable Pipetting) assessed across an expanded McFarland range
B. The automatic dilution mode (Auto Load & Go) assessed with a standard McFarland range
C. The manual dilution mode (Manual Load & Go) assessed with a standard McFarland range
The test cards were categorized as each product class of gram-negative (GN), gram-positive (GP), Streptococcus (ST) and yeast (YS) with the list of indicated organisms per antimicrobial. All GN, GP and ST challenge isolates were sub-cultured twice onto trypticase soy agar and incubated appropriately at 35 ± 2 °C, for 18 – 24 hours (GN and GP) or 18 – 20 hours (ST) before testing. All yeast isolates were sub-cultured twice onto Sabouraud dextrose agar and incubated at 35 ± 2 °C for 24 hours. Four different VITEK PRO and VITEK 2 60 instruments operated by four different operators were used to test isolated colonies of representative isolates of different species of Enterobacterales, Acinetobacter spp., Pseudomonas aeruginosa, Staphylococcus spp., Streptococcus spp., Enterococcus spp., and Candida spp. Table 8 shows the test antimicrobial agents and organism groups used for the AST challenge study.
Table 8. List of Organism group and Antimicrobial Agents for Challenge Study
| AST card | Organism group | Antimicrobial Agents |
| --- | --- | --- |
| GN AST card | Enterobacterales, Acinetobacter spp., and Pseudomonas aeruginosa | Amoxicillin/clavulanic acid, Aztreonam, Cefazolin, Cefepime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Ertapenem, ESBL, Meropenem/vaborbactam, Minocycline, Tigecycline, Tobramycin, Trimethoprim/sulfamethoxazole |
| GP AST card | Enterococcus spp., Staphylococcus spp., and Streptococcus spp. | Ampicillin, Cefoxitin Screen, Clindamycin, Daptomycin, Erythromycin, Gentamicin High Level, Linezolid, Moxifloxacin, Nitrofurantoin, Oxacillin, Streptomycin High Level, Tetracycline, Vancomycin |
| ST AST card | Streptococcus spp. | Benzylpenicillin, Ceftriaxone, Clindamycin, Erythromycin, Inducible Clindamycin Resistance, Levofloxacin, Linezolid, |
K262683 - Page 10 of 12
{11}
| AST card | Organism group | Antimicrobial Agents |
| --- | --- | --- |
| | | Tetracycline, Trimethoprim/sulfamethoxazole, Vancomycin |
| YS AST card | Candida spp. | Caspofungin, Fluconazole, Micafungin |
The MIC results obtained using the VITEK PRO were compared to the MIC results obtained using the VITEK 2 manual mode. Essential Agreement (EA) was defined as MIC results obtained from the VITEK PRO that were within one doubling dilution of the MIC results obtained from the VITEK 2. For YS AST card, EA was defined as MIC results obtained from the VITEK PRO that were within two doubling dilutions of the MIC results obtained from the VITEK 2. Since this is a method-to-method comparison, results for all drug/organism combinations were evaluated together and were considered acceptable if the EA was ≥95%.
Overall performance of AST card results was >95% for GN AST card (n=628, including screening results), GP AST card (n=558, including screening results), ST AST card (n=436, including screening results), and YS AST card (n=131 results) for all dilution modes, which is acceptable.
The overall performance was established using the data for all drug/organisms combined for each card. Performance with the GN AST card was 613/628 (97.6%), 620/628 (98.7%), and 622/627 (99.2%) of MIC results within one doubling dilution of the comparator results with the Variable Pipetting, Auto Load & Go, and Manual Load & Go, respectively. All purity plates (100%) exhibited monomicrobial growth.
The overall performance of each mode with the GP AST card was 551/558 (98.7%), 553/558 (99.1%), and 555/558 (99.5%) of MIC results within one doubling dilution of the comparator results with the Variable Pipetting, Auto Load & Go, and Manual Load & Go, respectively. All purity plates (100%) exhibited monomicrobial growth.
The overall performance of each mode with the ST AST card was 435/436 (99.8%), 435/436 (99.8%), and 435/436 (99.8%) of MIC results within one doubling dilution of the comparator results with the Variable Pipetting, Auto Load & Go, and Manual Load & Go, respectively. All purity plates (100%) exhibited monomicrobial growth.
The overall performance of each mode with the YS AST card was 131/131 (100%), 131/131 (100%), and 131/131 (100%) of MIC results within two doubling dilutions of the comparator results with the Variable Pipetting, Auto Load & Go, and Manual Load & Go, respectively. All purity plates (100%) exhibited monomicrobial growth.
Given the large volume of data, Table 9 summarizes the results for each dilution method and mode stratified by AST card only. The cumulative reporting and stratification by each AST card are presented for simplicity and are based on the analysis for each drug/organism combination which revealed acceptable high degree of agreement between VITEK PRO and VITEK 2 instruments.
K262683 - Page 11 of 12
{12}
Table 9. Summary of EA Results, Stratified by AST Card and Dilution Mode
| AST Card | Number (%) of MIC values within essential agreement (EA) | | |
| --- | --- | --- | --- |
| | VITEK PRO Variable Pipetting | VITEK PRO Auto Load & Go | VITEK PRO Manual Load & Go |
| GN | 613/628 (97.6%) | 620/628 (98.7%) | 622/627* (99.2%) |
| GP | 551/558 (98.7%) | 553/558 (99.1%) | 555/558 (99.5%) |
| ST | 435/436 (99.8%) | 435/436 (99.8%) | 435/436 (99.8%) |
| YS | 131/131 (100%) | 131/131 (100%) | 131/131 (100%) |
* One no-growth was recorded when tested with cefepime using VITEK PRO Manual Load & Go.
##### 5. Carry-Over:
Not applicable.
#### B Other Supportive Instrument Performance Characteristics Data:
Electrical safety and electromagnetic compatibility (EMC) testing were performed, and the system was found to be acceptable.
Software and cybersecurity documentation was reviewed and found to be acceptable.
#### VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
#### IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
K262683 - Page 12 of 12
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Guidance alerts
New and changed FDA guidance documents, emailed as a daily digest.
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the ? button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only Software as a Medical Device, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (Software as a Medical Device), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.